CTMX

CytomX Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-16

Figures on this page computed 2026-11-08 12:40 UTC

Last close

2.35USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-16

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself
-22.8%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
-99.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
0.04Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.17 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.18x

0.30x

1.49x

0.35x

0.30x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-16

Sales1.18x
Its own average over 10 years, 64.7M.
Profit0.30x
Its own average over 10 years, -58.6M.
Free cash flow1.49x
Its own average over 10 years, -50.8M.
Debt0.35x
Its own average over 10 years, 12.0M.
Price0.30x
Its own average over 11 years, 8. Market data, 2026-11-04

Profit is furthest from its own average, at 0.30 times.

Sales is 1.18 times its own 10-year average; Profit is 0.30 times its own 10-year average; Free cash flow is 1.49 times its own 10-year average; Debt is 0.35 times its own 10-year average; Price is 0.30 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-16

Sales against its own 10-year average1.18
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
The filing itself
Profit against its own 10-year average0.30
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.49
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
The filing itself
Debt against its own 10-year average0.35
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
The filing itself
Price against its own 11-year average0.30Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD